Challenges and Barriers to Reimbursement

Getting psychedelic therapies approved and paid for by healthcare systems is challenging. While these treatments show promise for mental health conditions, their unique approach—combining drugs with psychotherapeutic support—creates hurdles not seen with regular medicines. This chapter consolidates and summarises many of the challenges highlighted in earlier chapters, setting up the solutions discussed in the "Solutions and Recommendations" chapter.

Interviews with regulators, insurance companies, healthcare providers, and industry experts reveal key barriers at every stage, from clinical trials and proving effectiveness to securing reimbursement and insurance coverage. The hybrid nature of psychedelic therapies, combining pharmacological and psychotherapeutic components, adds particular complexity. Healthcare systems typically evaluate and fund drugs or therapy services separately, not together. As a result, systems may undervalue these treatments or delay access because their frameworks cannot effectively assess and implement these unique combined features.

This chapter examines clinical evidence challenges, economic barriers around costs and benefits, regulatory hurdles across different countries, healthcare system implementation issues, social and ethical concerns, public perception, and resistance from various stakeholders with conflicting goals. Understanding these challenges is essential for developing effective solutions that can help psychedelic therapies reach patients who need them while ensuring they are used safely and cost-effectively within modern healthcare systems.

Clinical Evidence Challenges

Providing solid evidence for psychedelic therapies is more complicated than for regular medicines. These treatments combine powerful drugs with psychotherapeutic support, making it harder to design objective clinical trials and track how well therapies perform. There are several significant hurdles: studies often include only certain types of patients, it is difficult to blind participants on whether they received the active drug or not, and comparing these treatments to existing options is not straightforward.

Another significant challenge is understanding how well these treatments work over extended periods of time. Most studies only follow patients for a few weeks or months, which is insufficient to determine whether the benefits persist or what kind of ongoing care people might need. Research must also demonstrate how these treatments perform in real-world healthcare settings, not just in carefully controlled research studies. These evidence gaps make it harder for health authorities to decide whether to approve and pay for these treatments.

Trial Design Limitations

Small Samples and Selection Bias

Many early psychedelic trials have relied on small, highly selective patient groups, raising concerns about their generalisability to broader populations. Participants in these studies are often highly motivated, well-educated, and financially stable—factors that enable them to take time off work, travel to trial sites and commit to time-consuming treatments.

These participants may not reflect the demographics of patients most in need of treatment in real-world settings, where barriers such as socioeconomic limitations, geographic isolation, and coexisting health conditions are more prevalent. As a result, the efficacy observed in controlled trials may be difficult to replicate in routine clinical practice.

Another issue is that most data on psychedelics comes from the United States, where healthcare systems and cultural views differ from those in Europe. Some studies suggest that European patients might not respond as strongly to psychedelic therapies as American patients, possibly due to different expectations, social settings, or how treatments are delivered.

Blinding and Psychedelic-Induced Effects

Blinding—keeping patients and doctors from knowing who received the actual drug—is especially challenging in psychedelic research because these substances cause noticeable mental effects. Unlike regular medicines, psychedelics create clear changes in thinking and perception, making it more likely that participants and therapists will correctly identify whether they received the actual drug or a placebo.

While other treatments with noticeable effects, like sedatives, face similar issues, the problem is more prominent with psychedelics because their effects are so intense. This challenge requires creative approaches to trial design, but creating these new methods complicates achieving regulatory approval.

Researchers have tried to mitigate unblinding by using active placebos or lower doses of the active drug. However, this raises concerns because even these control conditions can produce meaningful therapeutic effects, complicating the interpretation of results.

Comparator Selection and Cost Constraints

Choosing appropriate comparison treatments is another major challenge in psychedelic trials. European regulators usually require new treatments to have at least a comparable risk-benefit ratio as existing ones, and payers also want to be able to evaluate comparative effectiveness. For psychedelics, which often treat resistant conditions and combine drug effects with psychotherapeutic support, identifying appropriate comparators can be difficult.

The unique mechanisms of psychedelics, combining pharmacological effects with psychotherapeutic support, make them difficult to compare against traditional monotherapies. The comparison challenge has led some stakeholders to propose hybrid models that assess both components independently, though such approaches risk oversimplifying the treatment model and missing its synergistic effects.

The situation is made more challenging by high costs. Comparative trials with combination therapies are expensive and take longer to complete. Developers may lack the money or willingness to run such trials. These financial and practical challenges slow evidence generation and make it harder to prove value to payers.

Regulatory Expectations and Novel Trial Designs

The EMA and other regulators have not yet created clear rules or guidance for evaluating psychedelic therapies as a class, which further complicates trial design. Current requirements follow traditional drug testing models, focusing on standard dosing and symptom reduction. While these conventional approaches are important, they may not fully capture the unique therapeutic mechanisms and outcomes of psychedelic treatments, including improvements in overall well-being and quality of life.

With no previous psychedelic approvals in Europe outside of esketamine (Spravato), regulators might demand comprehensive evidence, including multiple large trials and long-term follow-up. This regulatory uncertainty has significant implications beyond just market approval. Even if regulators accept novel trial designs, such as the use of active placebos, the lack of formal guidance means that country payers may reject these studies for not meeting their established assessment criteria. This dual challenge of regulatory and reimbursement uncertainty has led some companies to focus on markets with clearer paths, like the U.S., instead of Europe.

Limited Long-Term Data

Gaps in Long-Term Follow-Up

One of the most pressing challenges for psychedelic therapies is likely to be the scarcity of data to determine their longer-term efficacy. While early trials, including small-scale academic studies and Phase II clinical trials, have shown promising short-term results, they often lack the extended follow-up periods necessary to capture the durability of effect and potential adverse outcomes.

Most psychedelic trials report outcomes measured in weeks or months, leaving uncertainties about whether the initial gains—such as reductions in depressive symptoms or post-traumatic stress—persist over years. This absence of longer-term data raises uncertainties for regulators and payers, who require robust evidence to justify reimbursement, especially where treatment costs are higher, and investment to support long-term adoption within healthcare systems.

Adding to this issue is the nature of psychedelic treatments, which often involve profound subjective experiences and a degree of psychological restructuring. These effects may vary in stability, with some patients experiencing relapses or requiring ongoing psychotherapy to maintain benefits. Whether long-term improvements hinge on repeated dosing, booster sessions, or continued psychological support remains largely unresolved.

Without this information, it becomes difficult to estimate the true cost-effectiveness of psychedelic interventions, particularly for health systems that operate under budgetary constraints.

Challenges of Real-World Evidence Collection

Even when studies track patients long-term, the results can be inconclusive. Many participants in early psychedelic trials are highly motivated and may seek additional treatments outside the trial, like joining support groups or using psychedelics on their own. The participants' outside activities make it hard to measure the effectiveness of the initial treatment alone.

Real-world results migh also be different to those seen in carefully controlled trials. While research studies have highly motivated patients and experienced therapists, regular medical practice differs. Patients might not follow treatment plans strictly, therapists might have less training, and people might be less engaged overall.

Cost Implications of Long-Term Support

The full long-term costs of psychedelic therapies remain unknown. While these treatments often involve just a few intensive sessions over several weeks, patients might need ongoing support. The extended care could include follow-up therapy sessions, support groups, or additional doses to maintain benefits. The uncertainty around extra costs complicates calculations of true treatment costs and widespread implementation potential.

For instance, many patients join support groups after treatment, but these groups operate outside regular healthcare systems. The informal nature of support groups makes it hard to track their effectiveness or determine whether patients need more formal care. Insurance companies and health authorities might be reluctant to cover psychedelic treatments without a better understanding of these ongoing needs, especially since the cost argument for these therapies relies heavily on their long-term benefits.

Economic Evaluation Challenges

Working out whether psychedelic therapies provide good value for money is particularly challenging. These treatments have high upfront costs—not just for the drugs themselves but also for the therapy sessions, infrastructure use, and trained staff needed to deliver them safely. While supporters argue these treatments could save money in the long run by helping people recover from severe mental health problems, proving these savings is difficult without long-term evidence.

Another challenge is measuring how these treatments might benefit society. While it is relatively easy to count direct savings like reduced hospital stays or less medication use, it is much harder to put a value on indirect benefits. These could include people being able to return to work, families spending less time caring for ill relatives, or reduced societal costs from problems like addiction. Different European countries also have different ways of measuring these benefits and deciding what makes a treatment worth paying for, complicating things further.

High Upfront Costs of Combined Treatment

High Costs of Psychedelic Drugs

The cost of psychedelic therapies is likely to be a significant challenge. While manufacturing these drugs might be relatively cheap, developers rationalise higher drug prices based on the argument that they need to cover development and approval costs, cover costs of other failed medicines, and continually invest in pharmacovigilance and evidence generation even after launching a medicine. For example, Spravato (esketamine) costs thousands of euros per treatment course, indicating that psychedelic drugs might cost similar amounts per course of treatment.

Health authorities evaluate whether treatments are worth the cost. If drug prices are too high, reimbursement might only be granted for certain patients or under specific conditions. The price negotiations create tension between companies that aim for higher prices and payers and insurers that try to control costs, especially for treatments that might help hard-to-treat conditions but lack long-term evidence.

Psychotherapy and Resource-Intensive Delivery

Beyond drug costs, psychedelic treatments might require substantial therapeutic support. While the dosing sessions can last several hours and need continuous healthcare provider oversight, there is ongoing debate about the optimal amount of preparation and integration therapy. Some proponents advocate for intensive psychotherapy to achieve the best outcomes, while others suggest a more minimal approach focused on ensuring patient safety.

For example, MDMA therapy protocols can involve up to 100 hours of therapist time. Based on cost modelling from U.S. studies, these resource requirements could lead to total treatment costs of €15,000 to €40,000 per patient, reflecting the drug price and extensive therapeutic support needed.

Current systems frequently assess drugs or therapy separately for reimbursement, not both together. Since psychedelic drugs and psychotherapeutic support may require use together, any attempts to separate out their effects complicates value-for-money calculations. The interconnected nature of drugs and psychotherapeutic support creates uncertainty in defining value and appropriate cost for the drug-only part of therapy and justifying reimbursement at higher price points.

Short-Term Costs vs. Long-Term Benefits

These treatments must balance high initial costs against possible but uncertain long-term health outcomes and savings. While they might reduce future spending on medications, hospital stays, and lost work time, there is currently not enough long-term evidence to prove these savings. When health systems focus on short-term budgets, expensive treatments often face resistance, even if they might save money later.

The cost-benefit uncertainty could lead to limited reimbursement and insurer coverage, such as coverage only for patients who have not responded to a set number of other treatments. Finding ways to consider long-term benefits while managing current costs remains a key challenge.

Measuring Indirect Benefits

Quantifying Societal and Economic Gains

Distinguishing Direct and Indirect Benefits

The direct economic benefits of psychedelic treatments are easy to measure—things like fewer hospital stays and less medication use. When a patient recovers from depression or PTSD using psychedelics, we can capture how much less they use health services. These savings can be estimated using standard methods.

However, the indirect socioeconomic benefits are more challenging to measure but just as important. These benefits include people being able to work better, needing less help from family, and having better relationships. Mental health problems often make it hard for people to work and live normally. Fixing these issues can benefit society broadly, but it is harder to put numbers on these benefits.

Challenges in Valuing Productivity Gains

One big challenge is measuring how many more people can work after treatment. While patients might return to work or do better at their jobs, it is hard to capture how much of this improvement comes from the treatment versus other factors like the economy or education.

There are different ways to calculate these work benefits. One method considers all the money someone might earn over time, while another only counts short-term gains since others eventually fill jobs. Neither method is perfect—one might show too much benefit while the other might show too little. The calculation differences make it hard to agree on the value of these treatments.

Reducing Caregiver Burden and Improving Quality of Life

Beyond individual productivity, psychedelic therapies may alleviate burdens placed on caregivers—family members and friends who often provide unpaid support to individuals struggling with mental illness and may have had to give up full-time employment due to the demands of caregiving. Mental health conditions often require lots of support from others, who might have to help with daily tasks and provide emotional support. Good treatment can reduce this burden, letting caregivers work more and live better lives.

However, measuring these benefits is even more challenging than measuring productivity gains. Current methods are not good at putting a monetary value on things like caregiving, even though they are crucial for families and society.

Addressing Long-Term Societal Impacts

It is also hard to measure long-term benefits. While psychedelic treatments might help people for many years or decades, most calculations only look at short-term savings. These short-term evaluations might undervalue these treatments, especially when considering fewer disability payments and less need for government help.

For instance, addiction disorders generate significant public costs through increased criminality, violence, and social care interventions. Successful treatments could reduce these substantial societal burdens, along with decreasing disability payments and the need for ongoing government support.

Real-world results might differ from expectations. Support groups might improve treatments, but calculations rarely consider these benefits. Limited access to follow-up care might also reduce long-term benefits. These factors complicate predictions of the treatments' actual economic value.

Variability in Health Economic Standards

Different Countries, Different Rules

European countries have different ways of deciding whether to pay for new treatments. Some countries like the Netherlands and Sweden may consider all benefits, including helping people return to work and reducing family burdens. Others, like Germany, prioritise patient-relevant outcomes with no formal economic analysis. This disparity means that developers must make different arguments for each country.

In countries that consider wider benefits, psychedelic treatments might have a better chance of demonstrating value to payers and securing favourable pricing and broader reimbursement. However, demonstrating payer-accepted value will be more challenging in countries that only look at direct healthcare costs, even if they help patients and society in other ways.

Varying Methods and Cost Limits

Countries also use different methods to calculate benefits and have different limits for what they will pay. The UK usually will not pay more than £30,000 per year of healthy life gained, while the Netherlands allows higher costs for more serious conditions. Germany takes a different approach, negotiating prices case by case without set limits.

Evidence Requirements and Market Access

Countries handle uncertainty about new treatments differently. Some approve treatments while gathering more evidence about long-term effects, while others wait for complete proof, which can delay access to treatment. These differences make it hard to get psychedelic treatments approved across Europe. Companies usually focus on countries with larger populations first, which means smaller countries wait longer. The prioritisation of larger markets creates an unequal system in which access to these potentially valuable treatments varies widely depending on where patients live.

Regulatory and Policy Barriers

Getting psychedelic therapies approved and regulated presents unique challenges because most countries classify these substances as Schedule 1 drugs with no accepted medical use. Developers must overcome hurdles beyond the usual medicine approval process by dealing with drug control authorities and health regulators. While some controlled substances like esketamine have successfully become approved medicines for depression, complex and expensive requirements create barriers through special permits, secure storage, and strict safety measures.

Different countries' varying approaches to these treatments complicate the approval process. Countries maintain individual rules about controlled substances and different systems for funding new treatments. The regulatory and payment variations impede the widespread availability of psychedelic therapies, especially since most healthcare systems lack frameworks specifically designed for combined drug-therapy treatments. The multiple requirements create a complex web that developers must navigate, often delaying patient access in some countries.

Controlled Substance Regulations

Legal Restrictions and Scheduling

Current Legal Status

International law classifies most psychedelics like psilocybin, MDMA, and LSD as Schedule I drugs. The Schedule I status labels them as highly dangerous with no medical use. The restrictive classification makes treatment and research challenging. Anyone working with these drugs needs special permits, secure storage, and strict safety measures. The strict requirements make operations more expensive and complicated, deterring many hospitals and researchers from working with psychedelics.

Examples of Change

Some controlled drugs have successfully become medical treatments, showing that change is possible. Medical professionals first used ketamine as an anaesthetic, but now regulators have approved a form of it (esketamine) to treat depression. Doctors prescribe GHB (sodium oxybate), another controlled drug, to treat sleep disorders under the brand names Xyrem and Xywav.

However, getting approval for psychedelics will likely take longer and be more difficult. Regulators want extensive evidence that these drugs are safe and work well, especially since the treatment includes therapeutic support along with the drugs. They often require ongoing studies even after approval to keep checking safety, which adds more costs and complexity to the process.

Practical Challenges

Rescheduling psychedelics from Schedule I to a lower schedule creates a significant hurdle before doctors can prescribe them in health systems. The rescheduling process demands extra effort, delays patient access, and increases uncertainty around market entry.

Even after rescheduling, substantial practical challenges remain. Healthcare facilities will likely need special storage arrangements and maintain detailed prescribing records, which adds costs and administrative burdens. Additionally, healthcare providers will need specific training and certification to use these drugs, but no recognised training programs are available yet.

This shortage of qualified providers could become a significant bottleneck, limiting access to treatment even if the drugs become legally approved. These regulatory requirements, high handling costs, and limited training opportunities make it harder for healthcare systems to adopt these treatments, even if they prove effective.

Complex Approval Processes

Extra Regulatory Steps

Getting approval for psychedelic treatments is more complicated than for regular medicines. These treatments need two types of approval: one as a medical treatment and another because they are controlled substances. The dual approval process requires coordination with both health authorities and drug control agencies. Each step needs lots of paperwork, safety checks, and facility inspections. The combination of drugs with psychotherapeutic support adds complexity. Regulators evaluate the drug components and therapy elements separately, making it difficult to demonstrate the treatment's overall effectiveness.

Higher Costs and Longer Timelines

These extra steps make developing psychedelic treatments more expensive and time-consuming. Companies must follow both medical and drug control rules, which means more paperwork and longer waiting times. A prolonged process is especially challenging for smaller companies developing psychedelic treatments, as they often have limited money and time compared to big pharmaceutical companies. When regulators ask for more long-term safety data or extra trials, it increases costs and delays.

Different Views on Approval

There is a debate about how psychedelics should be approved. Drug companies focus on getting approval for their specific versions, like Compass’ COMP360 for psilocybin. Nevertheless, some supporters want broader changes to make all forms of psychedelics available, including natural ones. These opposing views create a challenge. Specific drug approvals keep tight controls but limit access and keep costs high. In contrast, broader access might make treatments cheaper but more challenging to control for quality and safety, and for use only in appropriate patients.

Implications for Market Access

These complex approval processes affect how quickly treatments become available. Treatment centres might wait to invest in facilities and staff training until they know regulations and payment systems. The lengthy approval process also slows down the development of support systems needed to provide these treatments widely. All these challenges make it more complex and more expensive to bring psychedelic treatments to patients who need them and create more significant uncertainties for return on investment, which is important for commercial drug developers.

Lack of Established Reimbursement Pathways

Novelty of Combined Therapies

Challenges in Integrating Drug and Therapy Models

Psychedelic therapy is different from most medical treatments because it combines drugs with psychotherapeutic support sessions. The therapeutic part potentially involves long sessions with trained professionals, special facilities, and follow-up care, which adds significant costs beyond just the drug itself. Healthcare systems may find it difficult to define whether this should be considered one complete treatment or separate parts that need different kinds of payment. Treatment periods and therapy quantities vary significantly depending on the condition and psychedelic type, making healthcare providers unable to define 'complete care packages' upfront.

National health systems face a particular challenge because they often divide funding among different parts of the system. Healthcare systems will have to choose between treating psychedelic therapy as one complete treatment or breaking it into separate parts. When broken into parts, the drug might be paid for through typical drug payment systems, while the therapy sessions are paid through separate mental health budgets.

This split approach causes problems because it might not recognise how the drug and therapy work together to help patients. It could also mean insufficient money is available for either part of the treatment, making it harder for patients to access the complete treatment they need. In contrast, insurer-based reimbursement systems might be better equipped to handle combined treatment approaches as a single package.

Creating New Payment Systems

Healthcare systems need to develop new ways to pay for these combined treatments. Some possible solutions include "bundled payments" covering everything in one package or performance-based payments based on the treatment's effectiveness. However, changing payment systems is complicated and takes time. Countries must also decide whether to pay for these treatments based on their mental health or drug budgets. Mental health budgets are often stretched, which could limit access, while drug budgets might struggle with the extra therapy costs.

Questions About Long-Term Value

Another challenge is proving that these treatments are worth their cost in the long run. Early research suggests they might save money by reducing the need for other healthcare services and helping people return to work. However, without long-term evidence, insurance companies and healthcare systems might hesitate to pay the high upfront costs. Developers will need to keep collecting evidence even after approval, which adds more costs.

Implications for Market Access

These payment challenges affect how quickly treatments become available. Healthcare systems might start with small trial programs to test different payment methods. However, this careful approach could mean that treatments take longer to become widely available. Making these treatments part of regular healthcare will require new systems for selecting appropriate patients, delivering treatment, and monitoring results. Healthcare systems, insurance companies, other payer groups, and developers need to work together to create payment systems that are fair and sustainable.

Policy Inconsistencies Across Countries

Fragmented Regulatory and Reimbursement Frameworks

Countries will handle the approval and payment for psychedelic therapies in very different ways. This fragmentation complicates the process for developers to getting approval and reimbursement in multiple countries. Each country has its own system for deciding if treatments are worth paying for and how much they should cost.

Examples of Country Differences

Germany has one national system (AMNOG) for evaluating treatments and negotiating prices, with insurers directly involved in pricing decisions. The UK has separate systems for England and Wales, Scotland, and Northern Ireland, each making its recommendations for the local health services providers to implement. The Netherlands evaluates treatments nationally through ZiN, but insurance companies can still make their own rules about payment. The Czech Republic uses SÚKL for national assessments but lets insurers add more requirements.

Regional Differences Within Countries

Even within countries, access to treatments can vary by region. In Spain and Italy, different regions can make their own decisions about funding treatments. While public health insurance follows one system in Germany, private insurance companies can make other choices around the provision of care. Regional differences and insurance types determine whether patients can access specific treatments.

Costs for Drug Developers

Drug manufacturers must prepare separate pricing and reimbursement applications for each country, which requires expertise, time, and money. They must create documents that comply with each country's specific rules about evidence and analyses, provide a clear pricing rationale, and prove that the treatment will be effective in the local health system.

The combined drug-therapy nature of psychedelic treatments forces companies to provide complex explanations about their interdependence. Small biotech companies, which make up most psychedelic drug developers, face additional difficulties due to their limited resources and expertise in navigating Europe's complex HTA processes. Smaller countries might have to wait longer for these treatments because companies focus first on larger markets where they can reach the most patients with their first reimbursement applications.

These differences between countries make it harder to make all treatments widely available in a timely matter, and this is especially true for innovative therapies such as psychedelics. Some efforts—such as the Joint Clinical Assessment—have been made to make parts of the process similar across EU countries over time. However, developers still need to deal with many different systems for now.

Infrastructure and Implementation Challenges

Even if psychedelic therapies get approved and funded, healthcare systems face significant practical challenges in actually delivering these treatments. These treatments need facilities with dedicated rooms for long sessions, secure drug storage, and specially trained therapists who might work with just a few patients each week. Hospitals and clinics may lack the setup required for this kind of care, and there are not enough trained professionals to provide it. Without established professional networks to help develop guidelines and training programs, individual facilities must independently figure out these complex requirements, making it harder to implement these treatments widely and effectively.

Limited Clinical Infrastructure

Facility Requirements and Physical Space Limitations

Psychedelic therapy requires dedicated spaces that most hospitals and clinics do not currently have available. While the physical setup requirements are relatively modest—requiring mainly a comfortable reclining chair or bed, soft lighting, calming decor, and a quiet environment—the main challenge lies in dedicating these spaces for extended periods. Treatment sessions lasting 6-8 hours mean these rooms are occupied for long stretches, significantly reducing the number of patients that can be treated compared to regular outpatient services. This extended room occupation could impact cost-effectiveness and limit a facility's ability to provide other treatments.

The availability of appropriate space is likely to be the primary infrastructure challenge, particularly affecting access patterns. Finding and dedicating suitable rooms may be especially difficult for small clinics and those in rural areas. Additionally, facilities need special secure drug storage following strict regulations. As a result, psychedelic treatments are likely to be concentrated in larger urban facilities, particularly in inpatient and acute care settings, at least initially. This concentration in bigger cities could create significant access barriers for people in other areas seeking treatment.

Workforce Limitations and Training Gaps

Another big problem is finding enough trained therapists. Psychedelic therapy needs special training beyond regular therapy skills.[24]1 Therapists must know how to help patients through intense experiences and handle any challenging reactions, and they need to learn about the pharmaceutical characteristics of these novel treatments. Two therapists are usually present in clinical trials, limiting the workforce available if this requirement translates to real-world practice.

Currently, there are no recognised training programs, and it is uncertain whether the certification of current programmes will be retrospectively recognised. This uncertainty creates a tricky situation: Therapists do not want to get training if they are not sure they will find work, but clinics cannot offer treatments without trained therapists. Since each treatment might include many intense hours, even trained therapists can only work with one to a few patients weekly.

Another significant challenge is creating sufficient financial incentives for established therapy providers to transition to psychedelic therapies, given the time commitment and additional training requirements compared to conventional therapeutic or drug-based approaches.

Lack of Professional Support

A further challenge is that advocacy groups and professional networks dedicated to supporting the implementation of psychedelic therapies are still in their early stages and relatively fragmented. While other fields, such as oncology or cardiology, benefit from highly organised professional societies that lobby for funding, develop clinical guidelines, and promote public awareness, psychedelic therapies have not yet developed this level of institutional presence and coordination.

The limited presence of established patient and professional advocacy groups hinders securing funding, creating treatment guidelines, and educating the public. Their absence reduces pressure on healthcare systems to include these treatments and weakens support for policy changes and funding for training programs.

Broader Systemic Challenges

Many healthcare systems in Europe already struggle with long waiting lists for mental healthcare. A lack of coordination between different types of care providers and small behavioural health budgets compounds this. Psychedelic therapy needs different healthcare providers to work together well, which is challenging in these disconnected systems. Also, many healthcare providers are used to prescribing medicine and might resist treatments that combine drugs with psychotherapeutic support. Changing these attitudes will take time and education.

Societal and Ethical Challenges

Using psychedelics as medical treatments raises complex social and ethical issues that go beyond typical healthcare concerns. These substances carry significant stigma from their history of recreational use and previous legal restrictions, which can make both the public and healthcare providers wary.

At the same time, serious ethical questions remain about patient safety, informed consent, and fair access to treatment. Since these therapies can powerfully affect how people think and feel, protecting vulnerable patients and providing treatments safely and equitably, rather than just to those who can afford private care, remains a critical priority.

Stigma and Public Perception

Past Problems with Image

Psychedelics have a complicated history that affects how people view them today. In the 1960s and 70s, protest movements and illegal drug use became associated with these substances. Media coverage emphasised dangerous experiences and mental health risks, leading governments to ban these drugs. The ban halted medical research for many years and created fears that still exist today.

Many older people and decision-makers still remember the warnings about these drugs from that time. Even though science now shows these substances might help treat mental health problems, many people still see them as dangerous illegal drugs. This old reputation makes it harder to get treatments approved and funded. Some healthcare providers might also worry about offering these treatments because they do not want to damage their professional reputations.

News Coverage Today

While recent media coverage has become more balanced, highlighting both therapeutic potential and safety concerns, public perception remains volatile. The media serves a dual role—raising awareness of therapeutic benefits while also providing important public safety oversight by reporting on adverse events or misuse. However, individual negative incidents can still overshadow scientific progress and reignite historical concerns.

Impact on Policy and Reimbursement Decisions

How society views psychedelics affects political and funding decisions. When people are scared of these substances, decision-makers might be too careful, making it harder to get treatments approved or funded. On the other hand, when media coverage makes these treatments sound like miracle cures, it can create unrealistic hopes. People might lose trust when the treatments do not live up to these high expectations.

Developers of psychedelic treatments need to find a balance between addressing old fears and avoiding overselling the benefits. Finding this balance requires careful communication with the public and ongoing conversations between scientists, healthcare providers, and government officials. Scientists, healthcare providers, and government officials must base their decisions on facts rather than fears or hype.

Ethical Considerations

Patient Safety and Informed Consent

Keeping patients safe during psychedelic therapy presents unique challenges. Unlike regular treatments, patients cannot fully know what to expect because these treatments change how they think and feel. The unpredictable nature of each person's subjective response makes it difficult for patients to understand what they agree to. These uncertainties raise questions about whether patients can give informed consent.

Moreover, many patients may have valid reasons for not wanting to experience these altered states, whether due to personal preferences, cultural beliefs, past experiences, or other concerns. Healthcare providers must respect these preferences and carefully consider them during initial patient selection and consent discussions.

Treatment centres need strict safety rules to protect patients. These include careful education before treatment, clear explanations of risks, and the right to stop treatment if necessary. Patients are often more easily influenced during treatment, which could make them vulnerable to manipulation. Cases of therapists misbehaving—both in conventional therapeutic settings and specifically within psychedelic trials and treatments—have shown why strict rules about professional behaviour and special training for therapists are needed.

Fair Access to Treatment

Cost is a major ethical concern. Psychedelic therapy can cost anywhere from a few thousand euros to well into the five figures per treatment course, which means only wealthy people might be able to afford it privately. While European countries will likely fully or partially pay for treatment through their healthcare systems, access restrictions mean that many people still might not be able to get these treatments.

This problem is worse for people who already have trouble getting healthcare. People in rural areas or from minority communities often have less access to mental healthcare. If psychedelic therapy is only available in big cities or specific regions, this makes the problem worse. Also, some communities might not trust these treatments, especially if few therapists are from their cultural backgrounds.

Creating Ethical Guidelines

Healthcare systems need clear rules for providing these treatments fairly and safely. This includes setting professional standards, ensuring therapists are adequately trained, and having ways to hold people accountable if something goes wrong.

While this section highlights key ethical challenges, equitable access and fairness issues require deeper exploration. In the "Ensuring Equitable Access" chapter, we will examine strategies to promote accessibility, reduce disparities, and create sustainable pathways for implementation across diverse populations. This analysis will include recommendations for policy reforms and practical initiatives so that psychedelic therapies fulfil their transformative potential without reinforcing existing inequities.

Stakeholder Resistance and Misalignment

Making psychedelic therapies work in healthcare systems requires collaboration between many different groups, but these groups often have conflicting priorities and concerns. Healthcare payers worry about high costs and uncertain benefits, while developers need to cover their research expenses and satisfy investors. Regulators want extensive safety data, but patients and advocacy groups push for quicker treatment access. Healthcare providers have practical concerns about facilities and training, while insurance companies focus on immediate costs rather than potential long-term savings.

These different goals and priorities create significant barriers to implementing these treatments effectively, especially since many companies developing them are smaller startups without established relationships in healthcare systems.

Payer Reluctance

Concerns About Risk and Uncertainty

Healthcare payers are likely to demonstrate significant hesitation towards psychedelic therapy due to its limited track record in modern clinical settings. The relative novelty of these treatments, combined with a scarcity of longitudinal data regarding efficacy and safety outcomes, will like create substantial barriers to widespread coverage approval.

These interventions present unique challenges beyond traditional pharmacological treatments, requiring specialised infrastructure, therapeutic support, and prolonged treatment sessions. This complexity introduces variables that make risk assessment and cost projection particularly challenging for payers.

Despite improving public sentiment towards psychedelics, isolated adverse events or misuse incidents can significantly influence coverage decisions. Healthcare payers remain hesitant to approve coverage, and the lack of coordinated advocacy from healthcare professionals creates little institutional pressure for implementation.

Budget Constraints and Competing Priorities

Healthcare systems face increasingly constrained budgets, and psychedelic therapy presents substantial upfront costs. While proponents argue for potential long-term cost reductions through decreased hospitalisation rates and reduced conventional treatment needs, these projected savings remain largely theoretical, pending longitudinal economic data.

In resource allocation decisions, HTAs and payers typically prioritise interventions with more immediate and quantifiable outcomes, particularly for acute or life-threatening conditions. While psychedelic therapy shows promise for achieving significant short-term health gains in areas like depression, suicidal ideation, anxiety, addiction, and eating disorders, key challenges remain. Success will depend not only on the cost-effectiveness of these treatments but also on the ability to deploy or reassign existing resources in these already resource-constrained areas of healthcare.

Systemic Evaluation Framework Limitations

Current HTA frameworks present structural obstacles to evaluating psychedelic therapies effectively. These systems, optimised for conventional pharmaceutical interventions, may struggle to adequately assess treatments with more subjective outcome measures and complex therapeutic components. The inability to properly evaluate the synergistic effects of combined drug-therapy interventions can result in fragmented assessments that may undervalue the comprehensive benefits of psychedelic therapy.

The absence of appropriate reimbursement categories for integrated treatment modalities forces evaluation through traditional pharmaceutical assessment pathways, potentially leading to unfavourable determinations that do not accurately reflect the treatment's full therapeutic value.

Divergent Stakeholder Objectives

Different Goals Among Key Stakeholders

The development of psychedelic therapy involves stakeholders with differing priorities. Commercial developers focus on proving efficacy, securing regulatory approval, and delivering financial returns to offset research costs and satisfy investors. These pressures can drive efforts to accelerate approval, reduce the psychotherapy component, and cut costs.

HTAs and regulators take a careful approach, requiring strong evidence of safety and effectiveness. They often want extensive long-term data before reimbursing new treatments. Insurance companies and healthcare systems primarily worry about immediate costs, which can clash with companies promoting expensive treatments that might only save money years later.

Healthcare providers have concerns about practical issues like facilities, training, and payment. Meanwhile, patients and advocacy groups often want these treatments available as quickly as possible, even before all the evidence is available. These different priorities create tension and make it harder to implement these treatments effectively.

Communication Problems and System Barriers

Many companies developing psychedelic treatments are smaller startups that lack established relationships with regulators and insurance companies.[25]2 While this independence can promote innovation, it also makes it more challenging for them to understand and work within existing healthcare systems.

The lack of coordination between different groups causes other problems. Assessment agencies might focus too narrowly on the drug aspect, missing the importance of therapy and specialised treatment settings. Insurance companies might look at costs without fully considering the broader benefits that drug developers emphasise.

Working Towards Better Cooperation

These challenges are not unique to psychedelic therapy, but they are more pronounced because these treatments are new and complex. Solving these problems requires new ways for different groups to work together while maintaining appropriate safety standards and cost controls. Early discussions between groups and flexible payment agreements could help bridge some of these gaps.

The implementation of psychedelic therapy confronts multiple barriers spanning scientific, clinical, economic, regulatory, and social dimensions. The next chapter will explore potential solutions and opportunities to overcome these obstacles and expand these treatments' applications and availability within healthcare systems.